- Home
- BMRC vs RCKT Comparison
BMRC vs RCKT Comparison
Compare BMRC & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRC
- RCKT
- Stock Information
- Founded
- BMRC 1989
- RCKT 1999
- Country
- BMRC United States
- RCKT United States
- Employees
- BMRC N/A
- RCKT N/A
- Industry
- BMRC Major Banks
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- BMRC Finance
- RCKT Health Care
- Exchange
- BMRC Nasdaq
- RCKT Nasdaq
- Market Cap
- BMRC 365.9M
- RCKT 328.6M
- IPO Year
- BMRC N/A
- RCKT N/A
- Fundamental
- Price
- BMRC $25.12
- RCKT $3.26
- Analyst Decision
- BMRC Buy
- RCKT Buy
- Analyst Count
- BMRC 4
- RCKT 13
- Target Price
- BMRC $26.25
- RCKT $12.96
- AVG Volume (30 Days)
- BMRC 83.8K
- RCKT 5.8M
- Earning Date
- BMRC 10-27-2025
- RCKT 11-06-2025
- Dividend Yield
- BMRC 4.06%
- RCKT N/A
- EPS Growth
- BMRC N/A
- RCKT N/A
- EPS
- BMRC 0.43
- RCKT N/A
- Revenue
- BMRC $93,409,000.00
- RCKT N/A
- Revenue This Year
- BMRC $59.17
- RCKT N/A
- Revenue Next Year
- BMRC $15.96
- RCKT $108.43
- P/E Ratio
- BMRC $56.98
- RCKT N/A
- Revenue Growth
- BMRC 59.35
- RCKT N/A
- 52 Week Low
- BMRC $19.11
- RCKT $2.19
- 52 Week High
- BMRC $27.11
- RCKT $22.01
- Technical
- Relative Strength Index (RSI)
- BMRC 65.64
- RCKT 50.38
- Support Level
- BMRC $23.86
- RCKT $3.16
- Resistance Level
- BMRC $24.82
- RCKT $3.40
- Average True Range (ATR)
- BMRC 0.53
- RCKT 0.27
- MACD
- BMRC 0.16
- RCKT -0.02
- Stochastic Oscillator
- BMRC 98.77
- RCKT 31.15
About BMRC Bank of Marin Bancorp
Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties and others. The majority of its revenue comes from interest income.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.